Ocugen, Inc. (OCGN) has seen an increase of 16.03% in the aftermarket. However, the last trading session closed at $5.24 with an increase of 4.38%.
Top 5 Tech Stocks to Buy in 2024
Don't let the chaos of rising interest rates, potential recession, tighter credit issues, higher oil prices, and incessant geopolitical issues chase you from the markets. Instead, just wait it out. With too much fear in the market, go bargain hunting with tech stocks. We have complied a report with the five of the best ways to profit within this industry.
"Top 5 AI Stocks to Buy in 2024."
Click here to sign up for our free report & newsletter, plus bonus offer "Elon Musk just Tiggered a BOOM in These Stocks"
Sponsored
COVAXIN (BBV152) Vaccine Candidate – What’s up?
On 15th December 2021, OCGN announced results from third-party research assessing immunological response after two doses of the vaccine candidate, COVAXIN (BBV152). For up to six months, researchers evaluated the immunological memory response of 71 vaccinated and 73 spontaneously infected participants with SARS-CoV-2, including variations of concern. In terms of antibodies, memory B cells, and memory CD4+ T cells, the study demonstrated that COVAXINTM (BBV152) developed a robust immunological memory against spike and nucleoprotein that was equivalent to that seen after spontaneous COVID-19 infection.
What’s Next?
The body’s immune response generates memory cells, such as memory B and T cells, in addition to treating infections. This allows for long-term viral protection. COVAXIN (BBV1542) was shown to create T-cells against both spike and nucleocapsid proteins in over 85% of the individuals in the study, and these T-cells lasted at least 6 months. Lastly, COVAXIN (BBV152) has been shown to induce long-term memory.
Phase 1/2 Clinical Trial for OCU400
OCGN reported on 9th December 2021 that the US Food and Drug Administration (FDA) has approved OCU400 (AAV-NR2E3). It is basically a modifier gene therapy candidate necessary for the therapy of retinitis pigmentosa based on genetic abnormalities in NR2E3 and Rhodopsin, for a clinical study. Ocugen’s modifying gene therapy platform intends to address nuclear hormone receptors (NHRs), which govern many processes in the retina, giving it the ability to treat a wide range of gene mutations – and, as a result, a wide range of retinal illnesses – with a single product. Conventional gene therapy, in which a functional form of a non-functional gene is transferred into target cells, focuses on just one genetic mutation at a time.
Now what?
OCU400’s advancement into clinical trials reflects the commitment to providing new alternatives to patients with genetic disorders where none presently exist. Moreover, the company is cooperating with premier eye care clinics, and they’ve been crucial in getting the study up and running and receiving patients. Lastly, OCGN is beginning on a new road of treatment with this revolutionary gene therapy.
